AMAG Pharmaceuticals reported a third-quarter net loss of $145,000, or 1 cent per share, compared with a net loss of $4 million, or 19 cents, a year earlier. The Waltham-based pharmaceutical company also said US sales of its Feraheme injection, which treats iron deficiency anemia in adults, were up 33 percent. During the quarter, AMAG also began promoting MuGard Mucoadhesive Oral Wound Rinse, which it licensed from Access Pharmaceuticals Inc. earlier this year. Full story for BostonGlobe.com subscribers.
This is a summary. To read the whole story subscribe to BostonGlobe.com
© Copyright 2013 Globe Newspaper Company.
Get the full story with unlimited access to BostonGlobe.com. Just 99¢ for 4 weeks.